Angiotech’s next frontier?
This article was originally published in The Gray Sheet
Executive Summary
High-volume orthopedics is the "next obvious place to go," President and CEO William Hunter says June 15 at Thomas Weisel Partners Growth Forum. Details of the firm's plan to "dip a toe" into the soft tissue market will be provided during the firm's analyst meeting June 24, Hunter noted. The Canadian drug company announced June 10 it has completed enrollment for the 60-patient European Vascular Wrap clinical trial six months ahead of schedule. An extra 20 patients have been added, and the study has been expanded from four to 12 sites...